AzTrials
AzTrials

Bowel PreparationPhase 3NCT03074448

Aquanet Bowel Cleansing Device Versus Oral Sodium Picosulfate for Pre-endoscopy Bowel Preparation

A Phase 3 study testing Aquanet and Sodium Picosulfate in people with Bowel Preparation, run by Kaiser Clinic and Hospital at 1 site in Brazil.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Poor or inadequate bowel preparation is one of the most common reasons for a repeated or failed colonoscopy. Preparation methods shown to be effective include the use of either bowel-cleansing devices or oral laxatives. Read more about this study

Who is it for?
Ages 14 to 90 years
Conditions the study is for
Bowel Preparation
What is being tested?
Aquanet and Sodium Picosulfate
Could I receive a placebo?
No, everyone receives an active treatment
How many people
314 participants
Where
1 siteBrazil
Study dates
May 2014to Sep 2015
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 14 to 90 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Men and women, aged 14-90 years
  • Must have had >3 spontaneous bowel movements per week for one month prior to the colonoscopy.
  • Willing and able to complete the entire process, comply with study instructions, and understand and sign the informed consent.

Who cannot join

  • Pregnancy (women of childbearing age underwent a pregnancy test at screening and again at randomization).
  • Acute abdominal surgical conditions (acute obstruction or perforation).
  • Prior colorectal surgery (excluding appendectomy), hemorrhoid surgery or endoscopic procedures.
  • Bowel disease (colon cancer history, toxic megacolon, toxic colitis, idiopathic pseudoobstruction, hypomotility syndrome).
  • Gastrointestinal disorders (active ulcer, output obstruction, retention, gastroparesis, ileus).
  • Upper gastrointestinal surgery (gastrectomy, gastric band, gastric bypass).
Show all 12Show fewer
  • Uncontrolled angina and/or myocardial infarction (MI) within the last 3 months; congestive heart failure (CHF) or uncontrolled hypertension.
  • Renal impairment (serum, creatinine and potassium must be within normal limits).
  • Participation in a research study within 30 days before receiving the study medication (or within 60 days for investigation of drugs with a half-life disposal of more than 15 days).
  • Hypersensitivity to active ingredients.
  • Chronic kidney disease.
  • Latex allergy

Trial locations and contacts

1 site in 1 country.

Brazil1 site
  • Kaiser Clinica and Day Hospital

    São José do Rio Preto, São Paulo

Other trials in Brazil

About this study

Official title: Aquanet Bowel Cleansing Device Versus Oral Sodium Picosulfate for Pre-endoscopy Bowel Preparation: Propensity Score Analysis for Interventional Effectiveness Evaluation

Poor or inadequate bowel preparation is one of the most common reasons for a repeated or failed colonoscopy. Preparation methods shown to be effective include the use of either bowel-cleansing devices or oral laxatives. Despite the acceptable effectiveness and safety of both bowel-cleansing methods, very few studies have been performed to evaluate which method is more effective. The main aim is to perform an observational study followed by propensity score modeling to evaluate and compare the quality of bowel preparation with the use of Aquanet bowel-cleansing devices versus the use of oral Sodium picosulfate solution. The study will involve 314 patients requiring a colonoscopy, between 14 and 90 years of age and with more than three bowel movements per week for the past one month. Outcomes of interest being the quality of bowel preparation evaluated through the Boston Bowel Preparation (BBP) scale. The investigator hypothesized that the bowel preparation with Aquanet bowel-cleansing device for colonoscopy will provide a better outcome for the patient than with conventional methods.

Read the detailed description

The study will compare the quality of pre-endoscopic bowel preparation using a bowel-cleansing device with oral Sodium picosulfate solution. The study will be described in accordance with the STROBE (Strengthening the Reporting of Observational studies in Epidemiology) guidelines.

Ethical aspects: The study will undergo full review by the local Institutional Review Board, all potential participants being provided with informed consent. Study protocol will only be initiated after consent is signed.

Settings: Data will be collected from June 2014 to February 2015 at the Portuguese Charitable Hospital, located in Sao Jose do Rio Preto/SP, Brazil. The Kaiser clinic, a private institution, will pay for the Aquanet devices. The Aquanet devices were designed and tested by Prime Pacific Health Innovations Corporation (http://www.primepacifichealth.com/aquanet-family-of-colon-hydrotherapy-devices/), and approved by the various regulatory authorities for market approval and licensing including FDA , Health Canada, and the European Union (<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K000031>, last accessed October 2016). The Aquanet devices have been on the market since 2001. The procedure lasts for 40-60 min, using filtered, ultraviolet treated water. Water pressure is derived from gravity or from a pump with an upper safe limit of two psi (per square inch) of pressure inside the colon. The device cleanses the large bowel through a series of fill and empty cycles by hydrating the colon, stimulating peristalsis and evacuating bowel contents. The process keeps the body hydrated without losing electrolytes. No adverse events have been reported for the Aquanet devices and there have also been no complaints received to its safety. It may cause mild abdominal discomfort during water infusion in some patients.

Participants: Inclusion criteria will involve all patients requiring a colonoscopy, those between 14 and 90 years of age, and with more than three bowel movements per week for the past one month. Patients will be excluded with following conditions: Pregnancy (confirmed by a pregnancy test), acute abdomen syndrome, prior colorectal surgery, hemorrhoids or endoscopic procedures, known bowel diseases (colon cancer history, toxic megacolon, toxic colitis, idiopathic pseudo obstruction, hypo-motility syndrome), other gastrointestinal disorders (active ulcer, output obstruction, retention, gastroparesis, ileus), previous upper gastrointestinal surgery (gastrectomy, gastric band, gastric bypass), uncontrolled angina and/or myocardial infarction (MI) within the last three months, congestive heart failure (CHF) or uncontrolled hypertension, renal impairment (serum, creatinine and potassium must be within normal limits) or known hypersensitivity to active ingredients. A total of 314 patients will be part of this analysis.

Outcome variables: Major outcome of interest will be the quality of bowel preparation as measured through the Boston Bowel Preparation (BBP) scale. Bowel preparation will be evaluated in three segments: The right segment (cecum and ascending colons), transverse segment (transverse colon including liver and splenic angles), and the left segment (descending and sigmoid colons and rectum). Each segment will be evaluated on a scale from 0-3, and the final score for an individual was the sum of scores for all three segments. Using this score, 0 was the minimum score corresponding to an unprepared colon and 9 was the maximum score corresponding to an excellent preparation without any residual traces.

Predicting variables: Main predictor will be the methods of bowel preparation. The bowel preparation will be done using either Sodium picosulfate or the bowel-cleansing device. On the eve of the examination, all participants on Sodium picosulfate will be given four tablets of Dulcolax with tea or water in the morning, liquid diet (juice, tea or water) at lunch, two capsules of 25mg Dramamine Capsgel in the afternoon, Sodium picosulfate dissolved in 150mL of cold water thirty minutes after, followed by drinking at least five 250-ml cups of water or other light liquids until midnight, with absolute fasting up to the time when the colonoscopy will be performed. For bowel preparation with the bowel cleansing device, intestinal lavage will be performed with the device, making use of water, pressure, and gravity to enhance bowel cleansing. The water used in this procedure will be previously triple-filtered by passage on carbon, micro-pellets and ultraviolet light. The preparation will be carried out by a trained nurse. All endoscopic procedures will be performed by an endoscopist who will be blinded to the method of preparation.

Being tested
Aquanet, Sodium Picosulfate
Keywords
Colonoscopy, Intestinal Cleaning, Picoprep, Aquanet

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AquanetDevice

    Aquanet bowel cleansing devices

  • Sodium PicosulfateDrug

    Sodium Picosulfate solution (Picoprep)

Study groups in NCT03074448
Study groupRoleWhat they receive
Sodium Picosulfate solution (Picoprep)Active comparatorOn the eve of the examination, all participants on Sodium picosulfate will take four tablets of Dulcolax with tea or water in the morning, liquid diet (juice, tea or water) at lunch, two capsules of 25mg Dramamine Capsgel in the afternoon, Sodium picosulfate dissolved in 150mL of cold water thirty minutes after, followed by drinking at least five 250-ml cups of water or other light liquids until midnight, with absolute fasting up to the time when the colonoscopy will be performed.
Receives: Drug: Sodium Picosulfate
Aquanet bowel cleansing devicesExperimentalFor bowel preparation with the bowel cleansing device, intestinal lavage will be performed with the device, making use of water, pressure, and gravity to enhance bowel cleansing. The water used in this procedure was previously triple-filtered by passage on carbon, micro-pellets and ultraviolet light. The preparation will be carried out by a trained nurse.
Receives: Device: Aquanet

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Quality of bowel preparation

    Evaluated through the Boston Bowel Preparation (BBP) scale.

    Measured: 16 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Mar 2017
  2. Study startMay 2014
  3. Primary completionSep 2014
  4. Study completionSep 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
314 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03074448
Sponsor's protocol ID
Kaiser CH
Status last verified
Mar 2017
First submitted
25 Apr 2016
Last updated
8 Mar 2017
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Aquanet and Sodium Picosulfate in people with Bowel Preparation, run by Kaiser Clinic and Hospital at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Quality of bowel preparation (time frame: 16 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Mar 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in